Pedersen, Maggie Fick and Bhanvi Satija COPENHAGEN (Reuters) -Wegovy-maker Novo Nordisk trimmed its full-year forecasts on ...

Participants in a multidisciplinary comprehensive obesity care model had clinically meaningful weight loss and high obesity ...

Investors got to hear Novo Nordisk’s side of the Metsera bidding war drama for the first time on Wednesday, as the company ...

Pfizer and Novo Nordisk are in a takeover clash over the obesity biotech Metsera, while some House Republicans warm to ...

The bank's lead analyst recognizes the importance of getting in early with potentially game-changing drug development.

Healthy people who suffer traumatic spinal injuries are at significantly greater risk for long-term chronic health conditions ...

Discover how Novo Nordisk's pipeline is being restructured to refocus its efforts on high-growth areas like diabetes and ...

Company cuts 9,000 jobs and lowers profit forecast as Wegovy sales slow. Q3 operating profit down 30% on competition ...

Novo Nordisk has lowered its full-year profit and sales forecasts amid slowed sales growth. However, a better-than-expected ...

Eli Lilly and rival drugmaker Novo Nordisk are the leading companies in the GLP-1 space, but others are emerging. Among them is Pfizer; in September that company announced it would acquire Metsera, a ...

Novo Nordisk once dominated the weight-loss drug market with Wegovy. However, rising competition, particularly from Eli Lilly ...

In a small study, patients who have successfully lost weight with weekly GLP-1 treatment maintain their weight loss and ...